Holistic Financial Partners Purchases 1,099 Shares of Eli Lilly and Company (NYSE:LLY)

Holistic Financial Partners increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 68,813 shares of the company's stock after buying an additional 1,099 shares during the period. Eli Lilly and Company comprises approximately 27.4% of Holistic Financial Partners' holdings, making the stock its largest position. Holistic Financial Partners' holdings in Eli Lilly and Company were worth $56,833,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. WestEnd Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company during the first quarter worth approximately $40,000. Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $43,000. Finally, O Brien Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY traded up $6.30 on Friday, reaching $811.73. The stock had a trading volume of 2,976,064 shares, compared to its average volume of 2,810,305. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The business's 50-day moving average price is $771.95 and its two-hundred day moving average price is $800.51. The company has a market cap of $769.30 billion, a P/E ratio of 66.05, a price-to-earnings-growth ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the previous year, the firm posted $2.58 EPS. The firm's quarterly revenue was up 45.2% on a year-over-year basis. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.74%. Eli Lilly and Company's payout ratio is 48.82%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Guggenheim increased their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a research note on Friday, July 11th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. One analyst has rated the stock with a sell rating, three have issued a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.